Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.45 |
| ▸ | CSF1R | P07333 | 2/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.34 |
| ▸ | MTOR | P42345 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4350687 | 0.82 | KCNH2 (0.42) | KCNH2 | |
| SCHEMBL1838608 | 0.82 | KCNH2 (0.39) | KCNH2PIK3CAMTOR | |
| SCHEMBL3430268 | 0.82 | KCNH2 (0.42) | KCNH2 | |
| SCHEMBL4350684 | 0.82 | KCNH2 (0.42) | KCNH2 | |
| SCHEMBL4214405 | 0.77 | KCNH2 (0.36) | KCNH2 | |
| SCHEMBL2823038 | 0.77 | KCNH2 (0.43) | KCNH2CSF1RPIK3CAMTOR | |
| SCHEMBL4214402 | 0.77 | KCNH2 (0.36) | KCNH2 | |
| SCHEMBL2822641 | 0.76 | KCNH2 (0.49) | KCNH2 | |
| SCHEMBL22013370 | 0.76 | KCNH2 (0.38) | KCNH2CSF1R | |
| SCHEMBL14358217 | 0.75 | KCNH2 (0.60) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2041145-B1 | AZATRICYCLIC COMPOUNDS AND THEIR USE | GLAXO GROUP LTD (GB) | 2010-10-27 | — | — | EP | disclosed |
| US-20100004230-A1 | AZATRICYCLIC COMPOUNDS AND THEIR USE | GLAXO GROUP LIMITED (GB) | 2010-01-07 | — | — | US | disclosed |
| EP-2041145-A1 | AZATRICYCLIC COMPOUNDS AND THEIR USE | Glaxo Group Limited (GB) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008003690-A1 | AZATRICYCLIC COMPOUNDS AND THEIR USE | GLAXO GROUP LIMITED (GB) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004230-A1 | AZATRICYCLIC COMPOUNDS AND THEIR USE | AADAC, AZI2, NNMT | KCNH2 2592/4885CSF1R 3575/4885PIK3CA 1571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.